WCN26-5489 Two cases of vanishing bile duct syndrome following initiation of avacopan therapy for ANCA-associated vasculitis

Read full text Summarise with VIRAT
Authors: Tomoka Watanabe, Keiji Kono, Kazuo Sakamoto, Katsuhito Kojima, Toshiyuki Hirai, Hayaki Okamoto, Kimihiko Goto, Shunsuke Goto, Hideki Fujii
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

【Background】Avacopan, a complement C5a receptor inhibitor, has emerged as a novel therapeutic option for ANCA-associated vasculitis (AAV), with well-established efficacy. Drug-induced liver injury (DILI) is the most common adverse event associated with avacopan. Recently, avacopan-induced vanishing bile duct syndrome (VBDS) has been reported, and some cases may progress to severe liver injury. However, its pathogenesis and optimal management remain unclear. Here, we report two cases of VBDS that developed after initiation of avacopan therapy for AAV.

Fields of Study & Subjects

Vasculitis and related conditions Drug-Induced Hepatotoxicity and Protection Complement system in diseases

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
103989–103989
Publication date
25 March 2026
Language
EN